Cargando…

A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer

OBJECTIVE: We aimed to evaluate the effectiveness of an mEOX (modified epirubicin, oxaliplatin plus capecitabine) regimen as second line therapy after failure of mDCF (modified docetaxel, cisplatin plus fluorouracil). METHODS: Gastic cancer patients for whom first-line therapy was unsuccessful and w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bozkaya, Yakup, Özdemir, Nuriye Yıldırım, Yazıcı, Ozan, Demirci, Nebi Serkan, Kurtipek, Alican, Erdem, Gökmen Umut, Ergün, Yakup, Zengin, Nurullah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844632/ https://www.ncbi.nlm.nih.gov/pubmed/29374414 http://dx.doi.org/10.22034/APJCP.2018.19.1.283

Ejemplares similares

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
por: Wang, Yan, et al.
Publicado: (2016)

Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?
por: Demirci, Nebi S., et al.
Publicado: (2017)

Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis
por: Ostwal, Vikas, et al.
Publicado: (2017)

Is the serum level of survivin, an antiapoptotic protein, a potential predictive and prognostic biomarker in metastatic pancreatic cancer?
por: Demirci, Nebi Serkan, et al.
Publicado: (2023)

Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer
por: Schønnemann, K R, et al.
Publicado: (2008)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
por: Waddell, Tom, et al.
Publicado: (2013)

The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial
por: Ahmadzadeh, Ahmad, et al.
Publicado: (2020)

Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma
por: Şendur, Mehmet A. N., et al.
Publicado: (2014)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
por: CHEN, WENJUN, et al.
Publicado: (2014)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer
por: Yang, Xiao-Hui, et al.
Publicado: (2020)

Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
por: Rhee, Jiyoung, et al.
Publicado: (2019)

A New Prognostic Parameter Associated With Recurrence in Patients With Nasopharyngeal Cancer Treated With Chemoradiotherapy: The Ratio of the Hemoglobin-to-Red Cell Distribution Width
por: Bozkaya, Yakup, et al.
Publicado: (2023)

Treatment Outcomes and Prognostic Factors in N3 Stage Gastric Cancer After Curative Resection: A Real World Data
por: Caliskan Yildirim, Eda, et al.
Publicado: (2023)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Recommendation for Resuming Elective Surgery during the Normalising Period in COVID-19 Pandemic
por: Sungur, Zerrin, et al.
Publicado: (2021)

Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
por: Baird, R, et al.
Publicado: (2011)

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
por: Peng, Jingyuan, et al.
Publicado: (2018)

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors
por: Ferrarotto, Renata, et al.
Publicado: (2013)

A Case of Complete Remission from Advanced Gastric Adenocarcinoma with Synchronous Liver Metastasis in Response to EOX Chemotherapy
por: Yan, Zhi-jun, et al.
Publicado: (2018)

Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2021)

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, Luigi, et al.
Publicado: (2009)

Tamoxifen in breast cancer survivors with COVID 19: stop or go?
por: Karacin, Cengiz, et al.
Publicado: (2021)

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
por: Rao, S, et al.
Publicado: (2008)

Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma
por: Wen, Feng, et al.
Publicado: (2016)

Neoadjuvant Capecitabine and Oxaliplatin Before Concurrent Capecitabine and Radiation in Locally Advanced Rectal Cancers: Experience of a Cancer Hospital in Pakistan
por: Mansha, Muhammad Atif, et al.
Publicado: (2021)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Identification of biomarkers predicting the chemotherapeutic outcomes of capecitabine and oxaliplatin in patients with gastric cancer
por: Zhang, Yan, et al.
Publicado: (2020)

Clinical and laboratory outcomes of the solid cancer patients reinfected with SARS-CoV-2
por: Ünsal, Oktay, et al.
Publicado: (2021)

A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
por: Starling, N, et al.
Publicado: (2009)

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer
por: Kim, Jung Han, et al.
Publicado: (2015)

Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study
por: Li, Anchuan, et al.
Publicado: (2022)

Clinicopathologic Features of Gastric Cancer in Young Patients
por: Seker, Metin, et al.
Publicado: (2013)

The Relationship Between Platelet–Lymphocyte Ratio, Neutrophil–Lymphocyte Ratio, and Survival in Metastatic Gastric Cancer on Firstline Modified Docetaxel and Cisplatinum Plus 5 Fluorourasil Regimen: A Single Institute Experience
por: Dogan, Mutlu, et al.
Publicado: (2015)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
por: Hwang, Seung Jae, et al.
Publicado: (2006)

Docetaxel, Oxaliplatin and Capecitabine (TEX) triplet regimen as adjuvant chemotherapy in resected gastric adenocarcinoma
por: Thumaty, Divya Bala, et al.
Publicado: (2021)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
por: Hatano, Akihiko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1bhsdc1r7cvqhimhg24cnjh0n1